STD Pharmaceutical Products Ltd, Plough Lane, Hereford HR4 0EL, United Kingdom.
Eur J Vasc Endovasc Surg. 2011 Apr;41(4):521-5. doi: 10.1016/j.ejvs.2010.12.012. Epub 2011 Jan 22.
The aim of this work was to quantify the volume of blood required to deactivate 1 ml of 3% sodium tetradecyl sulphate (STS).
A series of experiments were performed where the concentration of STS remaining in a stock solution was measured after adding increasing volumes of blood protein solutions.
Increasing volumes of bovine serum albumin, bovine erythrocytes and a mixture of both was added to a stock solution of STS. The BP manual titration method was used to measure the assay of the remaining STS.
The method was reproducible and increasing volumes of blood protein lowered the STS concentration in a linear fashion. Approximately 2 ml of a 4% blood protein solution deactivates 1 ml of 3% STS, which means approximately 0.5 ml of whole blood will deactivate 1 ml of 3% STS.
Sodium tetradecyl sulphate injection is deactivated by a relatively small volume of blood. The practical implication is that changes in technique to reduce the blood volume in larger veins and to introduce fresh aliquots of sclerosant along the length of the vein could improve the efficacy of sclerotherapy.
本研究旨在定量分析使 1ml3%十四烷基硫酸钠(STS)失活所需的血液量。
进行了一系列实验,在向 STS 储备溶液中加入不同体积的血液蛋白溶液后,测量剩余 STS 的浓度。
向 STS 储备溶液中加入不同体积的牛血清白蛋白、牛红细胞及其混合物。采用 BP 手动滴定法测量剩余 STS 的含量。
该方法具有可重复性,且随着血液蛋白体积的增加,STS 浓度呈线性降低。大约 2ml4%的血液蛋白溶液可使 1ml3%STS 失活,这意味着大约 0.5ml 全血可使 1ml3%STS 失活。
十四烷基硫酸钠注射液可被相对较小体积的血液失活。这一发现的实际意义在于,改变技术以减少较大静脉中的血液量,并在静脉长度上引入新鲜的硬化剂等分份,可能会提高硬化疗法的疗效。